EVOLENT HEALTH INC CLASS A (EVH)
Health Care · Specialty Care Management and Value-Based Healthcare Solutions · NYSE
Evolent Health connects specialty care for complex chronic conditions through evidence-based clinical pathways and provider networks aligned with payers to improve outcomes and reduce costs.
What EVOLENT HEALTH INC CLASS A does
Evolent Health is a market leader in specialty care management for people with complex chronic conditions including cancer, cardiovascular disease, and musculoskeletal disorders. The company works with health plans and risk-bearing payers to connect and coordinate evidence-based care across multiple specialties, using proprietary technology and high-performance provider networks to improve patient outcomes and reduce healthcare costs. The company's primary revenue comes from its Specialty Care Management Services solution, which combines provider networks, clinical pathways, and technology to align financial incentives with quality care.
Themes: Specialty care management, Value-based care and risk-bearing arrangements, Oncology care coordination, Cardiology care coordination, Musculoskeletal condition management, Evidence-based clinical pathways, Healthcare cost containment, Physician alignment and incentives
Fundamentals
- Price$4.74 as of 2026-08-21 close
- Market cap$536M as of 2026-08-21
- 1-year return-46.0% 2025-08-21 close $8.77 → 2026-08-21 close $4.74
- P/En/a negative earnings
- Net margin-24.1% as of 2026-08-24
- Gross margin+17.3% as of 2026-08-24
- ROE-99.2% as of 2026-08-24
- Debt / equity2.52 as of 2026-08-24
- Revenue growth (YoY)-4.5% as of 2026-08-24
- Revenue CAGR (3y)+11.5% SEC XBRL
- Beta0.97 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How EVH compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How EVOLENT HEALTH INC CLASS A looks technically
EVOLENT HEALTH INC CLASS A (EVH) is trading 21.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 31 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-07-22, pushing above its recent trading range. It is 53.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 21.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +21.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.76 | $4.76 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.90 | $3.90 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 31 trading days ago — a "golden cross", a bullish long-term signal | 31 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 21.5% above | +21.5% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 23.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 57.4 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($3.00 to $4.76) — its "stochastic" reading is 99 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 98.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.08 | $10.08 |
|---|---|---|
| From the 52-week high | it is 53.0% below its 52-week high (its highest price of the past year) | -53.0% |
| Above the 52-week low | it is 126.3% above its 52-week low (its lowest price of the past year) | +126.3% |
| Below the 52-week high | it is 53.0% below its highest point of the past year | 53.0% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-22, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $39.78 (set on 2022-09-15) | $39.78 |
| Given back of the 52-week move | over the past year its closes ranged ($2.17 to $9.99), and it has recovered roughly a third of its fall from last year’s high — 33% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.00 to $7.25. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 32.9% |
| From the all-time high | it is 88.1% below its all-time high | -88.1% |
| Nearest price level | it is trading 4.2% above a support level at $4.54 — a price it turned at twice since 2025-11-24, most recently on 2026-05-07. Since 2024-08-21 it has 3 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.2% |
| All-time low | its lowest closing price on record is $2.10 (set on 2026-04-02) | $2.10 |
| Above the all-time low | it is 126.3% above its all-time low | +126.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 81% of the past ~6 months) | 81st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3589 between its high and its low — about 7.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3589 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.71 and $5.14 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.71 – $3.93 – $5.14 |
| Typical daily range (% of price) | its price moves about 7.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.6% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges above its 200-day average price (21.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.53× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.3% since the prior reading | +0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.13 toward buy |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.1% |
|---|---|---|
| Open gap | it gapped 5.1% above the previous close 8 sessions ago and has not traded back through the level it left behind at 3.93 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.1% |
| Gap filled | a 3.5% gap down opened on 2026-07-29 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it took 6 sessions to close | 11 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +3.49% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 21.3 percentage points (the stock lost 19.0% while the market gained 2.3%) | -21.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 20.3 percentage points (the stock gained 23.4% while the market gained 3.1%) | +20.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 58.8 percentage points (the stock gained 69.9% while the market gained 11.1%) | +58.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 66.4 percentage points (the stock lost 46.0% while the market gained 20.5%) | -66.4% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 2.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 12.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -2.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 28% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.70 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +28.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $4.22 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +12.3% |
Price levels it has turned at before
EVH last closed at $4.74 on 2026-08-21. Since 2024-08-21 it has turned at 3 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.54 | Support | 4.2% below the last close | turned there twice · 2025-11-24 to 2026-05-07 |
| $4.26 | Support | 10.0% below the last close | turned there four times · 2025-12-15 to 2026-06-22 |
| $3.68 | Support | 22.4% below the last close | turned there three times · 2026-03-04 to 2026-05-27 |
| $8.31 | Resistance | 75.3% above the last close | turned there five times · 2025-03-05 to 2025-10-22 |
| $9.25 | Resistance | 95.2% above the last close | turned there four times · 2025-03-25 to 2025-07-29 |
| $9.69 | Resistance | 104.3% above the last close | turned there twice · 2025-01-22 to 2025-09-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.67 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$5.77 range $3.00 – $8.00; median $6.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EVH
- Consensus EPS estimate$0.06005 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Membership declines from Medicaid and ACA Health Exchanges due to regulatory changes, including impacts from the One Big Beautiful Bill Act (2025), could significantly reduce customer base and revenue.","Medical claims cost growth in performance-based contracts continues to exceed historical norms and revenue growth, eroding margins and profitability; company has limited ability to predict future cost trends.","Concentration risk with largest customers (Molina 24%, Aetna 20.7%, Cook County 15.4%) creates vulnerability to customer loss or pricing pressure."]
What changed in the latest 10-Q
AI-assisted comparison of EVH's 10-Q filed 2026-05-07 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to '2025 Form 10-K' instead of '2024 Form 10-K' in opening MD&A paragraph (filed 2026-05-07)
- Added reference to 'current reports on Form 8-K filed in 2026' instead of '2025' (filed 2026-05-07)
- Added new paragraph discussing Medicaid and ACA Health Exchanges changes caused by One Big Beautiful Bill Act during 2025, with specific reference to membership declines in Medicaid and Health Exchanges as of quarter ended March 31, 2026 (filed 2026-05-07)
- Added statement: 'During the quarter ended March 31, 2026, our customers reported membership declines in Medicaid and Health Exchanges consistent with our expectations' (filed 2026-05-07)
- Added reference to 'three months ended March 31, 2026' in Impact of Inflation section instead of 'three and nine months ended September 30, 2025' (filed 2026-05-07)
- Added new Customers table for quarter ended March 31, 2026, showing Aetna (20.7%), Blue Cross and Blue Shield of North Carolina, Centene Corporation, Cook County Health and Hospitals System (15.4%), Florida Blue (11.0%), and Molina Healthcare (24.0%) (filed 2026-05-07)
- Removed:
- Removed detailed discussion of June 19, 2025 Commitment Letter with Ares for Incremental Facility and October 15, 2025 maturity date of 2025 Notes (filed 2025-11-07)
- Removed discussion of August 7, 2025 exchange of Series A Preferred Stock for second lien term loan facility (filed 2025-11-07)
- Removed reference to '$6.0 million loss in related to the Incremental Facility in extinguishment of Series A Preferred Stock and other refinancing fees' (filed 2025-11-07)
- Removed paragraph discussing ACA Health Exchanges members during three months ended September 30, 2025 and expiration of premium tax credits at end of 2025 (filed 2025-11-07)
- Removed customers table for three and nine months ended September 30, 2025 and 2024 (filed 2025-11-07)
- Reworded:
- Changed 'as well as' to 'as well as' in Industry Climate section - no substantive change in phrasing but context updated from '2024' discussion
- Changed reference in Segment Reporting from 'assesses the performance of our operations, develops strategy and reviews financial information' to 'reviews financial information' (filed 2026-05-07)
- Replaced specific discussion of ACA Health Exchanges premium tax credit expiration in 2025 with broader language about Medicaid and ACA Health Exchanges changes caused by One Big Beautiful Bill Act (filed 2026-05-07)
- Updated Industry Climate section to replace 'Our results for the first three quarters of 2025' with 'Our results for 2025' (filed 2026-05-07)
- Notes:
- The newer filing text appears truncated at the Goodwill and Intangible Assets section, limiting full comparison of later MD&A content
- The older filing text is also truncated, limiting full assessment of complete section comparisons
- Comparison is based on partial sections due to truncation in both documents
Risk Factors
- Added:
- Added Item 5 'Other Information' section disclosing Retention Award Agreements approved May 5, 2026 for Messrs. Blackley, McCarthy and Weinberg totaling $1,890,000 with two installment payment dates (December 31, 2026 and July 1, 2027) conditioned on continued employment (filed 2026-05-07)
- Added Exhibit 10.1 Form of Retention Award Agreement to exhibit list (filed 2026-05-07)
- Added Exhibit 10.2 Form of Performance Stock Unit Award Agreement reference to exhibit list (filed 2026-05-07)
- Signatures dated May 7, 2026 with Mario Ramos as Chief Financial Officer and Aammaad Shams as Chief Accounting Officer and Controller (filed 2026-05-07)
- Removed:
- Removed entire 'Risks Relating to Indebtedness' section containing discussion of additional financing needs, conditional conversion features of 2029 Notes and 2031 Notes, ability to settle conversions in cash, and accounting treatment of convertible debt securities (ASU 2020-06) that was in 2025 filing (filed 2025-11-07)
- Removed detailed risk factor language regarding potential dilution from equity issuance, debt covenant restrictions, liquidity concerns, and fundamental change repurchase obligations (filed 2025-11-07)
- Reworded:
- Changed reference from '2024 Form 10-K' to '2025 Form 10-K' in Risk Factors Item 1A (filed 2026-05-07)
- Changed statement from 'Except as set forth below, there have been no material changes to our risk factors' with detailed risk disclosures to simplified statement 'There have been no material changes from the risk factors described in our 2025 Form 10-K for the quarter ended March 31, 2026' (filed 2026-05-07)
- Notes:
- The 2025 filing Risk Factors section appears truncated at end (text cuts off mid-sentence in ASU 2020-06 discussion), limiting ability to fully assess all removals
- Comparison is between different fiscal quarters (Q2 2026 ended March 31, 2026 vs Q3 2025 ended September 30, 2025) which may account for material differences in disclosed risks
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for EVH — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding EVH as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 14,355,963
- Reported value $32,731,596
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
EVH had 15,812,910 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
EVH had 14.0% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.63 days to cover at the same settlement.
- Reported short interest (shares) 15,812,910
- Short interest (% of shares outstanding) 14.0%
- Prior settlement (shares) 14,685,004
- Reported change 7.68%
- Days to cover (reported) 3.63
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Centene Corporation
- Molina Healthcare, Inc.
- Aetna (CVS Health)
- UnitedHealth Group
- Humana Inc.
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EVH vs…
Frequently asked questions
What does EVOLENT HEALTH INC CLASS A (EVH) do?
Evolent Health is a market leader in specialty care management for people with complex chronic conditions including cancer, cardiovascular disease, and musculoskeletal disorders. The company works with health plans and risk-bearing payers to connect and coordinate evidence-based care across multiple specialties, using proprietary technology and high-performance provider networks to improve patient outcomes and reduce healthcare costs.
What sector is EVOLENT HEALTH INC CLASS A (EVH) in?
EVOLENT HEALTH INC CLASS A (EVH) is classified in the Health Care sector. Its industry is Specialty Care Management and Value-Based Healthcare Solutions. It trades on NYSE.
Who are EVOLENT HEALTH INC CLASS A's (EVH) competitors?
Notable peers of EVOLENT HEALTH INC CLASS A (EVH) include Centene Corporation, Molina Healthcare, Inc., Aetna (CVS Health), UnitedHealth Group and Humana Inc.. This peer set is informational only — not financial advice.
Is EVOLENT HEALTH INC CLASS A (EVH) overbought or oversold right now?
EVOLENT HEALTH INC CLASS A (EVH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EVH come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.